CY1118891T1 - Συζευγμα ινσουλινης με χρηση θραυσματος ανοσοσφαιρινης - Google Patents
Συζευγμα ινσουλινης με χρηση θραυσματος ανοσοσφαιρινηςInfo
- Publication number
- CY1118891T1 CY1118891T1 CY20171100511T CY171100511T CY1118891T1 CY 1118891 T1 CY1118891 T1 CY 1118891T1 CY 20171100511 T CY20171100511 T CY 20171100511T CY 171100511 T CY171100511 T CY 171100511T CY 1118891 T1 CY1118891 T1 CY 1118891T1
- Authority
- CY
- Cyprus
- Prior art keywords
- insulin
- present
- anoshefrin
- connection
- vivo
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 10
- 102000004877 Insulin Human genes 0.000 title abstract 5
- 108090001061 Insulin Proteins 0.000 title abstract 5
- 229940125396 insulin Drugs 0.000 title abstract 5
- 238000001727 in vivo Methods 0.000 abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000001151 peptidyl group Chemical group 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Η παρούσα εφεύρεση αφορά ένα σύζευγμα ινσουλίνης που έχει βελτιωμένη διάρκεια και σταθερότητα in vivo, το οποίο παρασκευάζεται με ομοιοπολική σύνδεση ινσουλίνης με μια Fc περιοχή ανοσοσφαιρίνης μέσω ενός μη-πεπτιδυλ πολυμερούς, μια μακράς διάρκειας φαρμακοτεχνική μορφή που το περιέχει και μια μέθοδο παρασκευής αυτού. Το σύζευγμα ινσουλίνης της παρούσας εφεύρεσης διατηρεί την in vivo δραστικότητα του πεπτιδίου σε ένα σχετικώς υψηλό επίπεδο και αυξάνει αξιοσημείωτα την ημίσεια ζωή στον ορό αυτού, βελτιώνοντας με τον τρόπο αυτό σε μεγάλο βαθμό τη συμμόρφωση του φαρμάκου κατά τη θεραπευτική αγωγή με ινσουλίνη.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20100030575 | 2010-04-02 | ||
PCT/KR2011/002331 WO2011122921A2 (en) | 2010-04-02 | 2011-04-04 | An insulin conjugate using an immunoglobulin fragment |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1118891T1 true CY1118891T1 (el) | 2018-01-10 |
Family
ID=44712809
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171100511T CY1118891T1 (el) | 2010-04-02 | 2017-05-12 | Συζευγμα ινσουλινης με χρηση θραυσματος ανοσοσφαιρινης |
Country Status (29)
Country | Link |
---|---|
US (1) | US9492507B2 (el) |
EP (1) | EP2552474B1 (el) |
JP (2) | JP5990506B2 (el) |
KR (4) | KR20110111267A (el) |
CN (3) | CN105061601A (el) |
AR (1) | AR081066A1 (el) |
AU (1) | AU2011233800B2 (el) |
BR (1) | BR112012025166A2 (el) |
CA (1) | CA2795291C (el) |
CY (1) | CY1118891T1 (el) |
DK (1) | DK2552474T3 (el) |
ES (1) | ES2625686T3 (el) |
HK (2) | HK1216648A1 (el) |
HR (1) | HRP20170720T1 (el) |
HU (1) | HUE034406T2 (el) |
IL (1) | IL222319B (el) |
LT (1) | LT2552474T (el) |
MX (1) | MX341427B (el) |
MY (1) | MY152304A (el) |
NZ (1) | NZ603050A (el) |
PL (1) | PL2552474T3 (el) |
PT (1) | PT2552474T (el) |
RS (1) | RS56013B1 (el) |
RU (1) | RU2519073C1 (el) |
SG (1) | SG184366A1 (el) |
SI (1) | SI2552474T1 (el) |
TW (1) | TWI520746B (el) |
WO (1) | WO2011122921A2 (el) |
ZA (1) | ZA201208189B (el) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
PT2256134E (pt) * | 2003-11-13 | 2014-03-05 | Hanmi Science Co Ltd | Fragmento fc de igg para um veículo de fármaco e método para a preparação do mesmo |
PT3228320T (pt) | 2008-10-17 | 2020-03-26 | Sanofi Aventis Deutschland | Combinação de uma insulina e de um agonista do glp-1 |
AU2010317994B2 (en) | 2009-11-13 | 2014-03-06 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist and methionine |
MY180661A (en) | 2009-11-13 | 2020-12-04 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine |
AR081066A1 (es) | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
AR081755A1 (es) * | 2010-04-02 | 2012-10-17 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo |
US9981017B2 (en) | 2010-04-02 | 2018-05-29 | Hanmi Science Co., Ltd. | Insulin conjugate using an immunoglobulin fragment |
AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
US20140148384A1 (en) | 2010-08-30 | 2014-05-29 | Sanofi-Aventis Deutschland Gmbh | Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2 |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
UA113626C2 (xx) * | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
BR112014004726A2 (pt) | 2011-08-29 | 2017-04-04 | Sanofi Aventis Deutschland | combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2 |
AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
KR102041412B1 (ko) * | 2011-12-30 | 2019-11-11 | 한미사이언스 주식회사 | 면역글로불린 Fc 단편 유도체 |
AR090281A1 (es) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
AR091902A1 (es) * | 2012-07-25 | 2015-03-11 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de un conjugado de insulina de accion prolongada |
AR094821A1 (es) * | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
AR092862A1 (es) * | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion |
PH12018501454A1 (en) | 2012-11-06 | 2020-02-17 | Hanmi Pharm Ind Co Ltd | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglubin fragment |
PE20151409A1 (es) * | 2013-02-26 | 2015-10-07 | Hanmi Pharm Ind Co Ltd | Analogo de insulina novedoso y su uso |
BR112015018828B1 (pt) * | 2013-02-26 | 2024-01-30 | Hanmi Pharm Co., Ltd | Conjugado de insulina sítio-específico |
MY186423A (en) * | 2013-03-05 | 2021-07-22 | Hanmi Pharm Ind Co Ltd | Improved preparation method for high-yield production of physiologically active polypeptide conjugate |
TWI828269B (zh) | 2013-03-15 | 2024-01-01 | 美商百歐維拉提夫治療公司 | 因子ix多肽調配物 |
KR20200130511A (ko) | 2013-04-03 | 2020-11-18 | 사노피 | 장시간-작용 제형의 인슐린에 의한 당뇨병의 치료 |
AR096890A1 (es) * | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn |
AR096891A1 (es) * | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo |
CN116987172A (zh) | 2014-01-20 | 2023-11-03 | 韩美药品株式会社 | 长效胰岛素及其用途 |
CA2944138C (en) * | 2014-03-31 | 2023-06-20 | Hanmi Pharm. Co., Ltd. | Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage |
AR100639A1 (es) * | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
TWI684458B (zh) | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及glp-1/昇糖素雙重促效劑之治療糖尿病之組成物 |
EP3229828B1 (en) | 2014-12-12 | 2023-04-05 | Sanofi-Aventis Deutschland GmbH | Insulin glargine/lixisenatide fixed ratio formulation |
US10435542B2 (en) * | 2014-12-23 | 2019-10-08 | Bridestone Americas Tire Operations, LLC | Hemp oil-containing rubber compositions and related methods |
KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
US10894089B2 (en) | 2015-02-17 | 2021-01-19 | Hanmi Pharm. Co., Ltd. | Long-acting insulin or insulin analogue conjugate |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
US11052133B2 (en) | 2015-05-06 | 2021-07-06 | Protomer Technologies, Inc. | Glucose responsive insulins |
AR105616A1 (es) | 2015-05-07 | 2017-10-25 | Lilly Co Eli | Proteínas de fusión |
ES2784603T3 (es) | 2015-06-02 | 2020-09-29 | Novo Nordisk As | Insulinas con extensiones recombinantes polares |
UY36870A (es) | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
CN108348581B (zh) | 2015-09-04 | 2022-07-01 | 斯克利普斯研究所 | 胰岛素免疫球蛋白融合蛋白 |
MA43348A (fr) | 2015-10-01 | 2018-08-08 | Novo Nordisk As | Conjugués de protéines |
TWI774694B (zh) | 2016-09-23 | 2022-08-21 | 南韓商韓美藥品股份有限公司 | 具有降低對胰島素受體之親和力之胰島素類似物及其用途 |
DK3551209T3 (da) | 2016-12-09 | 2021-08-23 | Akston Biosciences Corp | Insulin-fc-fusioner og fremgangsmåder til anvendelse |
CN110545849A (zh) * | 2017-02-03 | 2019-12-06 | 韩美药品株式会社 | 具有增加的持续性的生理活性物质的缀合物及其应用 |
KR101941975B1 (ko) | 2017-03-17 | 2019-01-25 | 고려대학교 산학협력단 | Atpif1을 함유하는 당뇨 치료용 약학조성물 |
CA3054899A1 (en) | 2017-03-23 | 2018-09-27 | Hanmi Pharm. Co., Ltd. | Insulin analog complex with reduced affinity for insulin receptor and use thereof |
CN110505885A (zh) * | 2017-04-05 | 2019-11-26 | 诺和诺德股份有限公司 | 寡聚体延伸的胰岛素-Fc缀合物 |
JP2022502467A (ja) | 2018-10-10 | 2022-01-11 | ノヴォ ノルディスク アー/エス | オリゴマー伸長インスリン−fcコンジュゲートおよびそれらの医学的使用 |
AR127619A1 (es) | 2021-11-15 | 2024-02-14 | Lilly Co Eli | FORMULACIONES CONSERVADAS DE FUSIONES DE INSULINA-Fc |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01254699A (ja) * | 1988-04-05 | 1989-10-11 | Kodama Kk | インスリン誘導体及びその用途 |
SI0792290T1 (en) | 1993-09-17 | 2001-12-31 | Novo Nordisk As | Acylated insulin |
US6485726B1 (en) * | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US6936439B2 (en) * | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
US6924264B1 (en) | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
US6756480B2 (en) | 2000-04-27 | 2004-06-29 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
EP1355942B1 (en) | 2000-12-07 | 2008-08-27 | Eli Lilly And Company | Glp-1 fusion proteins |
US20060183197A1 (en) * | 2001-01-11 | 2006-08-17 | Andersen Kim V | Variant growth hormone molecules conjugated with macromolecules compounds |
AU2002303869B2 (en) | 2001-05-21 | 2007-08-16 | Novartis Ag | Pulmonary administration of chemically modified insulin |
SK2432004A3 (sk) * | 2001-12-20 | 2005-04-01 | Eli Lilly And Company | Inzulínová zlúčenina s protrahovaným účinkom |
US20040062748A1 (en) | 2002-09-30 | 2004-04-01 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
DK2599502T3 (en) | 2003-04-11 | 2017-04-18 | Antriabio Inc | Process for Preparation of Site-Specific Protein Conjugates |
EP1635872A4 (en) * | 2003-05-30 | 2008-01-02 | Alexion Pharma Inc | ANTIBODIES AND FUSION PROTEINS COMPRISING MODIFIED CONSTANT REGIONS |
CN101955527B (zh) * | 2003-08-05 | 2016-04-20 | 诺沃挪第克公司 | 新型胰岛素衍生物 |
US20090238838A1 (en) * | 2003-11-13 | 2009-09-24 | Hanmi Pharm. Ind. Co. Ltd. | Insulinotropic peptide conjugate using an immunoglobulin fc |
PT2256134E (pt) * | 2003-11-13 | 2014-03-05 | Hanmi Science Co Ltd | Fragmento fc de igg para um veículo de fármaco e método para a preparação do mesmo |
US20080207505A1 (en) | 2005-01-12 | 2008-08-28 | James Kenneth D | Bna Conjugates and Methods of Use |
WO2006086402A2 (en) * | 2005-02-08 | 2006-08-17 | Research Development Foundation | Compositions and methods related to soluble g-protein coupled receptors(sgpcrs) |
KR100754667B1 (ko) * | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물 |
UA94226C2 (ru) * | 2005-04-22 | 2011-04-26 | Амген Инк. | Пептидные токсины как терапевтические средства |
JP5846712B2 (ja) * | 2005-08-16 | 2016-01-20 | ハンミ サイエンス カンパニー リミテッドHanmi Scienceco.,Ltd. | 開始メチオニン残基が除去された免疫グロブリンFc領域の大量生産方法 |
EP2089052A4 (en) * | 2006-05-24 | 2011-02-16 | Peg Biosciences | POLYETHYLENE GLYCOL-BASED LINK COMPOUNDS AND BIOLOGICALLY ACTIVE CONJUGATES BASED ON SAID COMPOUNDS |
US20080280818A1 (en) * | 2006-07-21 | 2008-11-13 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
JP2008169195A (ja) * | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
WO2008084051A1 (en) | 2007-01-12 | 2008-07-17 | Novo Nordisk A/S | Mixtures of pegylated insulin and fast acting insulin for pulmonary administration |
US20090104210A1 (en) | 2007-10-17 | 2009-04-23 | Tota Michael R | Peptide compounds for treating obesity and insulin resistance |
TWI451876B (zh) | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
RU2483081C2 (ru) | 2008-07-23 | 2013-05-27 | Ханми Сайенс Ко.,Лтд.,Kr | Полипептидный комплекс, содержащий непептидильный полимер, обладающий тремя функциональными концами |
US20100055733A1 (en) * | 2008-09-04 | 2010-03-04 | Lutolf Matthias P | Manufacture and uses of reactive microcontact printing of biomolecules on soft hydrogels |
AR081066A1 (es) | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
-
2011
- 2011-04-01 AR ARP110101117A patent/AR081066A1/es active IP Right Grant
- 2011-04-04 MX MX2012011384A patent/MX341427B/es active IP Right Grant
- 2011-04-04 AU AU2011233800A patent/AU2011233800B2/en not_active Ceased
- 2011-04-04 SG SG2012072666A patent/SG184366A1/en unknown
- 2011-04-04 CN CN201510474558.8A patent/CN105061601A/zh active Pending
- 2011-04-04 ES ES11763093.9T patent/ES2625686T3/es active Active
- 2011-04-04 EP EP11763093.9A patent/EP2552474B1/en active Active
- 2011-04-04 RS RS20170437A patent/RS56013B1/sr unknown
- 2011-04-04 WO PCT/KR2011/002331 patent/WO2011122921A2/en active Application Filing
- 2011-04-04 KR KR1020110030868A patent/KR20110111267A/ko active Application Filing
- 2011-04-04 CN CN201180022035XA patent/CN102869371A/zh active Pending
- 2011-04-04 US US13/638,786 patent/US9492507B2/en active Active
- 2011-04-04 RU RU2012146663/15A patent/RU2519073C1/ru not_active IP Right Cessation
- 2011-04-04 CN CN201710519561.6A patent/CN107325170A/zh active Pending
- 2011-04-04 PT PT117630939T patent/PT2552474T/pt unknown
- 2011-04-04 PL PL11763093T patent/PL2552474T3/pl unknown
- 2011-04-04 DK DK11763093.9T patent/DK2552474T3/en active
- 2011-04-04 NZ NZ603050A patent/NZ603050A/en not_active IP Right Cessation
- 2011-04-04 MY MYPI2012004365 patent/MY152304A/en unknown
- 2011-04-04 LT LTEP11763093.9T patent/LT2552474T/lt unknown
- 2011-04-04 CA CA2795291A patent/CA2795291C/en not_active Expired - Fee Related
- 2011-04-04 JP JP2013502499A patent/JP5990506B2/ja not_active Expired - Fee Related
- 2011-04-04 BR BR112012025166-0A patent/BR112012025166A2/pt not_active Application Discontinuation
- 2011-04-04 HU HUE11763093A patent/HUE034406T2/en unknown
- 2011-04-04 SI SI201131187A patent/SI2552474T1/sl unknown
- 2011-04-06 TW TW100111784A patent/TWI520746B/zh not_active IP Right Cessation
-
2012
- 2012-10-09 IL IL22231912A patent/IL222319B/en not_active IP Right Cessation
- 2012-10-31 ZA ZA2012/08189A patent/ZA201208189B/en unknown
-
2015
- 2015-07-03 JP JP2015134519A patent/JP6231522B2/ja active Active
-
2016
- 2016-04-22 HK HK16104634.6A patent/HK1216648A1/zh unknown
- 2016-12-13 KR KR1020160169395A patent/KR20160150079A/ko not_active Application Discontinuation
-
2017
- 2017-05-12 CY CY20171100511T patent/CY1118891T1/el unknown
- 2017-05-15 HR HRP20170720TT patent/HRP20170720T1/hr unknown
-
2018
- 2018-04-09 HK HK18104573.7A patent/HK1245290A1/zh unknown
- 2018-09-21 KR KR1020180114173A patent/KR20180109792A/ko active Search and Examination
-
2020
- 2020-02-06 KR KR1020200014368A patent/KR20200018526A/ko not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1118891T1 (el) | Συζευγμα ινσουλινης με χρηση θραυσματος ανοσοσφαιρινης | |
CY1119183T1 (el) | Πεπτιδια λυσοσωμiκης στοχευσης και χρησεις αυτων | |
CY1121943T1 (el) | Πυρηνοφιλοι καταλυτες για συνδεση οξιμων | |
WO2011122923A3 (en) | Long-acting interferon beta formulation using immunoglobulin fragment | |
CY1121321T1 (el) | Παρασκευη συζευγματων αντισωματoς-μεϋτανσινoεiδoυς δια μιας μεθοδου μιας βαθμιδας | |
CY1121531T1 (el) | Συνθετικα τριτερπενοειδη και μεθοδοι χρησης στην αγωγη νοσου | |
MX2009007267A (es) | Un complejo insulinotropico usando un fragmento de inmunoglobulina. | |
CY1118265T1 (el) | Παραδοση θεραπευτικων παραγοντων στο κνς | |
CY1120137T1 (el) | Ενεσιμα σκευασματα βοτουλινικης τοξινης | |
CY1120670T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα μονοπατιου ιστικου παραγοντα (tfpi) | |
CY1121419T1 (el) | Αναστολη της φουκοσυλιωσης των πρωτεϊνων in vivo χρησιμοποιωντας αναλογα φουκοζης | |
EA202191210A1 (ru) | Способы лечения | |
CY1115354T1 (el) | Ενωσεις πεγκυλιωμενης ινσουλινης lispro | |
BR112013016772B8 (pt) | compostos, uso do composto e composição farmacêutica | |
EA201170040A1 (ru) | Терапевтические полимерные наночастицы, содержащие алкалоиды vinca, и способы их получения и применения | |
MX2018006844A (es) | Composicion para tratar la diabetes que comprende un conjugado de insulina de accion prolongada y un conjugado de peptido insulinotropico de accion prolongada. | |
EA201590622A1 (ru) | Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения | |
CY1115180T1 (el) | Επιλογες θεραπειας για τη νοσο του fabry | |
EA201000979A1 (ru) | Улучшенные связывающие молекулы на основе фибронектина и их применение | |
CY1115717T1 (el) | Νουκλεϊνικο οξυ που περιεχει ή κωδικοποιει εναν βλαστο-βροχο ιστονης και μια πολυ(α)αλληλουχια ή ενα σημα πολυαδενυλιωσης για αυξηση της εκφρασης μιας κωδικοποιουμενης πρωτεϊνης | |
AR075913A1 (es) | Metodo para preparar un conjugado polipeptidico fisiologicamente activo de sitio especifico | |
BR112012026801B8 (pt) | conjugados de pirrolobenzodiazepina direcionados, composição farmacêutica, uso dos mesmos para tratamento de uma doença proliferativa ou autoimune e ligante de medicamento | |
EA201000747A1 (ru) | Система и способ трансдермальной доставки и способ получения системы трансдермальной доставки | |
BRPI1012141A2 (pt) | conjugado de sirna e método de preparação do mesmo | |
CY1119850T1 (el) | Χρηση της μετφορμινης σε συνδυασμο με ενεργοποιητη γλυκοκινασης και συνθεσεων που περιλαμβανουν μετφορμινη και ενεργοποιητη γλυκοκινασης |